We have previously reported novel, highly potent and selective nucleoside inhibitors of varicella-zoster virus (VZV) bearing unusual fluorescent bicyclic base moieties (McGuigan et al., 1999) . These bicyclic furanopyrimidine nucleosides displayed potencies against various strains of VZV in cell culture that were approximately 300-fold higher than those of current anti-VZV agents, such as acyclovir. Our initial studies identified the absolute requirement of a long alkyl side-chain, with an optimal chain length of C8-C10, for antiviral activity (McGuigan et al., 1999) as typified by structures 1a-1c (Figure 1 ). The key consequence of the obligate long alkyl side-chain is the inherent lipophilicity of the bicyclic systems and we noted that the most active nucleosides had calculated octanol-water logP [ClogP] values in the range of 2.4-3.5 (ClogP version 1.0, Biobyte Corporation, Claremont, CA). With a view to further exploring the structure-activity relationships (SARs) of this class of compounds, we carried out several types of structural modification in the alkyl side-chain. In the first instance, we examined the effect of halogen substitution at the terminus of a nonyl side-chain and found that this was well tolerated; and notably with ClogP values of the ω-halo compounds falling roughly within the previously noted optimal range. We therefore, proposed a possible correlation between antiviral activity and overall compound lipophilicity and also reported on the negative impact on antiviral activity of enhancing the aqueous solubility of the bicyclic nucleosides (Brancale et al., 2000b) , this being attributed to the consequential impact on logP. More recently, we sought to constrain the highly flexible alkyl side-chains into more restricted conformations by the use of ring moieties, whilst retaining overall compound lipophilicity. Following the introduction of a phenyl group at the 6-position of the bicyclic base, between the furo ring and the alkyl side-chain, we observed an astonishing enhancement of both potency and selectivity against VZV . The new lead p-alkylphenyl bicyclic nucleosides, as typified by structures 2a-2g (Figure  1 ), displayed potencies that were, by comparison, approximately 50-fold higher than those for alkyl analogues of identical ClogP. In keeping with our proposed correlation, 
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Introduction
the ClogP values for the most active compounds of the series (2d-2f ) fell almost exactly into the optimal range observed with previous bicyclic analogues ( McGuigan et al., 2001) . Thus, in continuing our studies on the inclusion of an aryl group in the side-chain, we now sought to determine whether or not the exact positioning of the phenyl ring within the side-chain was of significance to antiviral activity. We decided to investigate the effect of phenyl substitution at the terminus of the side-chain and bearing in mind the apparent importance of lipophilicity, we designed analogues that were chemically isomeric to the lead palkylphenyl systems, and thus with similar ClogP values. It was hoped that this might further support our previous suggestion that enhanced antiviral activity of the lead palkylphenyl analogues was related to the reduced conformational freedom of the side-chain (McGuigan et al., 2001) . This manuscript describes the synthesis and biological evaluation of a novel series of bicyclic nucleoside inhibitors of VZV bearing terminal phenyl groups in the side-chain.
Materials and methods

Chemistry
The numbering of the bicyclic ring follows the recommended IUPAC nomenclature guidelines. The naming of compounds follows IUPAC nomenclature and/or standard accepted nomenclature for nucleoside chemistry.
For thin layer chromatography (TLC): precoated aluminium backed plates (60F254, 0.2 mm thickness; supplied by E. Merck AG, Darmstadt, Germany) were used and were developed by the ascending method. After solvent evaporation, compounds were detected by quenching of the fluorescence, at 254 nm or 366 nm depending on the compound, on irradiation with an ultraviolet lamp. For column chromatography: glass columns were slurry packed in the appropriate eluent under gravity, with silica gel (silica gel 60, particle size 35-70 mM, supplied by Fluka Chemika). Samples were applied as a concentrated solution in the same eluent or preabsorbed onto silica gel. Fractions containing the product were identified by TLC, pooled and the solvent removed in vacuo. Flash column chromatography was performed with the aid of a hand pump. 1 H and 13 C-NMR spectra were recorded on a Bruker Avance DPX300 spectrometer (300 MHz and 75 MHz respectively) and auto-calibrated to the deuterated solvent reference peak. Coupling constants ( J) are given in Hertz (Hz). All 13 C-NMR spectra were proton-decoupled. High resolution mass spectra were obtained courtesy of the University of Birmingham, Department of Chemistry (Birmingham, UK).
All anhydrous solvents were used as supplied by Aldrich Chemical Company. All nucleosides and solid reagents were either dried for several hours while being heated under high vacuum over phosphorus pentoxide or by coevaporation with dry pyridine. All glassware was oven- -5-ynyl-benzene (4d) . Lithium acetylenide-ethylenediamine complex (90%) (2.2 g, 21.3 mmol) was suspended in anhydrous pentane/dimethyl sulphoxide (DMSO) [7:3] (100 ml) and cooled to 0°C. A solution of (4-chlorobutyl)-benzene (1.8 g, 10.7 mmol) in DMSO/ether [1:1] (10 ml) was added and the reaction mixture was allowed to warm to room temperature and stirred (19 h). The reaction mixture was then quenched by the addition of a saturated solution of NH 4 Cl (50 ml) and water (50 ml). After extraction with diethyl ether (3×250 ml), the organic layer was washed with brine (2×100 ml), dried (MgSO 4 ) and filtered. The solvent was removed in vacuo and the crude residue was purified by silica column chromatography, using heptane/ether [9:1] as eluent. The product was obtained as a colourless oil (1.4 g, 86% -6-ynyl-benzene (4e) . This was prepared as described for (4d) above, from lithium acetylenide-ethylenediamine complex (90%) (1.2 g, 10.9 mmol) in pentane/DMSO [7:3] (100 ml) and (5-chloro-pentyl)-benzene (1.0 g, 5.5 mmol) in DMSO/ether [1:1] (10 ml). The crude residue was purified by silica column chromatography, using heptane/ether [9.1] as eluent, to give the product as a colourless oil (0.71 g, 76% 18.8, 28.8, 28.9, 31.4, 36.3 (5×CH 2 ), 68.6 (α-alkynyl), 85.0 (β-alkynyl), 126.1 (ArC), 128.7 (ArC), 128.8 (ArC), 142.9 (ipso-ArC). -7-ynyl-benzene (4f) . This was prepared as described for (4d) above, from lithium acetylenide-ethylenediamine complex (90%) (1.0 g, 10.2 mmol) in pentane/DMSO [7:3] (100 ml) and (6-chloro-hexyl)-benzene (1.0 g, 5.1 mmol) in DMSO/ether [1:1] (10 ml). The crude residue was purified by silica column chromatography, using heptane/ether [9:1] as eluent, to give the product as a colourless oil (0.58 g, 61%). δ H (CDCl 3 ) 7.38 (5H, m, ArH), 2.76 (2H, t, J 7.4 Hz, CH 2 Ph), 2.31 (2H, dt, J 7.3 and 2.4 Hz, CH 2 C≡CH), 2.08 (1H, t, J 2.4 Hz, HC≡C), 1.93-1.47 (8H, m, 4×CH2); δ C (CDCl 3 ) 18.5, 28.9, 29.09, 29.1, 31.6, 36.4 (6×CH2) , 68.7 (α-alkynyl), 85.1 (β-alkynyl), 126.1 (ArC), 128.5 (ArC), 128.8 (ArC), 143.2 (ipso-ArC). -8-ynyl-benzene (4g) . This was prepared as described for (4d) above, from lithium acetylenide-ethylenediamine complex (90%) (0.97 g, 9.5 mmol) in pentane/DMSO [7:3] (100 ml) and (7-chloro-heptyl)-benzene (1.0 g, 4.7 mmol) in DMSO/ether [1:1] (10 ml). The crude residue was purified by silica column chromatography, using heptane/ether [9.1] as eluent, to give the product as a colourless oil (0.90 g, 95%). δ H (CDCl 3 ) 7.41 (5H, m, ArH), 2.78 (2H, t, J 7.4 Hz, CH 2 Ph), 2.34 (2H, dt, J 7.2 and 2.2 Hz, CH 2 C≡CH), 2.10 (1H, t, J 2.2 Hz, HC≡C), 1.80-1.53 (10H, m, 5×CH 2 ); δ C (CDCl 3 ) 18.4, 28.9, 29.09, 29.1, 29.2, 31.6, 36.4 (7×CH 2 ), 68.9 (α-alkynyl), 85.2 (β-alkynyl), 126.0 (ArC), 128.7 (ArC), 128.8 (ArC), 143.2 (ipso-ArC).
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5-(4-Phenyl-1-butynyl)-2′-deoxyuridine (5b).
To a stirred solution of 5-iodo-2′-deoxyuridine 3 (0.8 g, 2.3 mmol) in dry dimethylformamide (DMF) (5 ml) at room temperature under a nitrogen atmosphere, were added diisopropylethylamine (0.8 ml, 4.5 mmol), but-3-ynyl-benzene (1.03 ml, 7.9 mmol), tetrakis(triphenylphosphine)palladium (0) (0.261 g, 0.23 mmol) and copper (I) iodide (86 mg, 0.45 mmol). The reaction mixture was stirred (20 hours, room temperature) and then concentrated in vacuo. The resulting residue was dissolved in dichloromethane (DCM)/methanol [1:1] (20 ml), an excess of Amberlite IRA-400 (HCO 3 -form) was added and the mixture was stirred (30 min, room temperature). The reaction mixture was then filtered, washed with methanol and the combined filtrate was evaporated to dryness. The crude residue was purified by silica column chromatography using ethyl acetate (EtOAc) as eluent. Trituration with DCM, followed by recrystallization from DCM/methanol gave the product as a cream solid (0.29 g, 37%). 
5-(5-Phenyl-1-pentynyl)-2′-deoxyuridine (5c).
This was prepared as described for (5b) above, from 5-iodo-2′-deoxyuridine 3 (0.8 g, 2.3 mmol), dry DMF (5 ml), diisopropylethylamine (0.8 ml, 4.5 mmol), pent-4-ynylbenzene (1.14 g, 7.9 mmol), tetrakis(triphenyl-phosphine)palladium (0) 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(benzyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (6a).
To a stirred solution of 5-iodo-2′-deoxyuridine 3 (1.0 g, 2.8 mmol) in dry DMF (5 ml) at room temperature under a nitrogen atmosphere, were added diisopropylethylamine (1.0 ml, 5.6 mmol), prop-2-ynyl-benzene (1.05 ml, 8.5 mmol), tetrakis(triphenyl-phosphine)palladium (0) (0.326 g, 0.28 mmol) and copper (I) iodide (109 mg, 0.56 mmol). The reaction mixture was stirred (20 h, room temperature) after which time, triethylamine (20 ml) and copper (I) iodide (108 mg) were added. The reaction mixture was then heated to reflux and stirred (5 h). The solvent was removed in vacuo and the resulting residue was dissolved in DCM/methanol [1:1] (20 ml). An excess of Amberlite IRA-400 (HCO 3 -form) was added and the mixture was stirred (30 min, room temperature). The reaction mixture was then filtered, washed with methanol and the combined filtrate was evaporated to dryness. The crude residue was purified by silica column chromatography, using (1) 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(phenethyl)-2,3-dihy-
drofuro [2,3-d]pyrimidin-2-one (6b) . To a stirred solution of 5-(4-phenyl-1-butynyl)-2′-deoxyuridine (5b; 0.2 g, 0.6 mmol) in methanol/triethylamine [7:3] (20 ml), at room temperature under a nitrogen atmosphere, was added copper (I) iodide (80 mg). The reaction mixture was then heated to reflux and stirred (5 h). The solvent was removed in vacuo and the crude residue was purified by silica column chromatography using DCM/methanol [95:5] 2-one (6c) . This was prepared as described for (6b) 
3-(2′-Deoxy
-β-D-ribofuranosyl)-6-(3-phenyl-1-propyl)- 2,3-dihydrofuro[2,3-d]pyrimidin-
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(4-phenyl-1-butyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (6d)
. This was prepared as described for (6a) above, from 5-iodo-2′-deoxyuridine 3 (0.9 g, 2.5 mmol) in dry DMF (20 ml), diisopropylethylamine (0.9 ml, 5.1 mmol), hex-5-ynylbenzene (4d; 1.20 g, 7.6 mmol), tetrakis(triphenyl-phosphine)palladium (0) (0.293 g, 0.25 mmol) and copper (I) iodide (97 mg, 0.51 mmol). The crude product was purified by silica column chromatography using EtOAc/methanol [95:5] as eluent. The solvent was removed in vacuo and trituration with methanol afforded the pure product as a white solid (0.80 g, 81% 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(5-phenyl-1-pentyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (6e)
. This was prepared as described for (6a) above, from 5-iodo-2¢-deoxyuridine 3 (0.5 g, 1.4 mmol) in dry DMF (20 ml), diisopropylethylamine (0.5 ml, 2.8 mmol), hept-6-ynylbenzene (4e; 0.60 g, 3.5 mmol), tetrakis(triphenyl-phosphine)palladium (0) (162 mg, 0.14 mmol) and copper (I) iodide (54 mg, 0.28 mmol). The crude product was purified by silica column chromatography using EtOAc/methanol 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(6-phenyl-1-hexyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (6f)
. This was prepared as described for (6a) above, from 5-iodo-2′-deoxyuridine 3 (0.47 g, 1.3 mmol) in dry DMF (20 ml), diisopropylethylamine (0.5 ml, 2.7 mmol), oct-7-ynyl-benzene (4f, 0.60 g, 3.2 mmol), tetrakis(triphenyl-phosphine)palladium (0) 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-(7-phenyl-1-heptyl)-
2, 3-dihydrofuro[2,3-d]pyrimidin-2-one (6g) . This was prepared as described for (6a) above, from 5-iodo-2′-deoxyuridine 3 (0.60 g, 1.8 mmol) in dry DMF (20 ml), diisopropylethylamine (0.6 ml, 3.6 mmol), non-8-ynylbenzene (4g, 0.90 g, 4.5 mmol), tetrakis(triphenyl-phosphine)palladium (0) 
3D structures
Structures of the p-pentylphenyl nucleoside (2e) and its isomeric pentyl-ω-phenyl compound (6e) were built in ChemDraw Ultra 7.0, and pasted into Chem3D Pro 5.0. Structures were energy minimised using MM2 (0.1 minimum RMS gradient), and then MOPAC with AM-1 force field (0.01 minimum RMS gradient). The two energyminimized structures were then overlaid to obtain maximal sugar and base overlap.
Virology
Cells. Human embryonic lung (HEL) fibroblasts and E6SM cells were grown in minimum essential medium (MEM) supplemented with 10% inactivated foetal calf serum (FCS), 2mM L-glutamine and 0.3% sodium bicarbonate.
Viruses. The laboratory wild-type VZV strains Oka and YS, the thymidine kinase-deficient VZV strains 07-1 and YS-R, herpes simplex virus type 1 (HSV-1; strain KOS), herpes simplex virus type 2 (HSV-2; strain G), the thymidine kinase-deficient HSV-1 strains B-2006 and VMW 1837, cytomegalovirus (CMV) strains Davis and AD-169 and vaccinia virus (VV) were used in the virus inhibition assays.
Antiviral assays. Confluent HEL cells grown in 96-well microtitre plates were inoculated with VZV at an input of 20 PFU (plaque forming units) per well. After a 1-2 h incubation period, residual virus was removed and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 2mM L-glutamine and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days by 50% as compared with untreated control.
Cytotoxicity assays. Confluent monolayers of HEL cells as well as growing HEL cells in 96-well microtitre plates were treated with different concentrations of the experimental drugs. Cell cultures were incubated for 3 (growing cells) or 5 (confluent cells) days. At the indicated times, the cells were trypsinized and the cell number was determined using a Coulter counter. The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%.
Results
The synthetic route (Figure 2 ) used to prepare the target compounds has been adapted from previously reported procedures (Robins & Barr, 1981 , 1983 Crisp & Flynn 1993) . The bicyclic nucleoside analogues (6a-6g) were synthesized via the coupling of terminal acetylenes (4a-4g) with 5-iodo-2′-deoxyuridine 3, in DMF under co-catalysis of Pd and Cu (McGuigan et al., 1999) . Alkynes 4a-4c were commercially available, while alkynes 4d-4g were prepared cleanly in good yields (61-95%) from the corresponding commercially available ω-chloroalkyl benzenes by treatment with lithium acetylide-ethylenediamine complex (Nyström et al., 1988) . The intermediate 5-alkynyl nucleosides, 5 were then cyclized in the presence of copper (I) iodide to give the target bicyclic systems, 6 in moderate to good yields. We have previously noted (McGuigan et al., 1999) that the 5-alkynyl intermediates may be isolated and purified prior to cyclisation or may be cyclized in situ. For the first two cases studied (5b and 5c) the intermediates were isolated and purified (37% and 42%, respectively) and subsequently cyclized to give 6b (22%) and 6c (54%). However, in all other cases (5a, 5d-5g) the 5-alkynyl nucleosides were not isolated and 5-iodo-2′-deoxyuridine 3 was converted to 6a, 6d-6g in a single step. The yields obtained from the single step procedures were found to be considerably higher than the overall yields for compounds 6b and 6c. The target structures 6a-6g were characterized by 1 H and 13 C NMR and high resolution mass spectrometry, with all data being consistent with their intended structures.
The target bicyclic systems (6a-6g) were evaluated for their ability to inhibit the replication of VZV, HSV-1, HSV-2, VV and CMV according to described methods (De Clercq et al., 1986) . Data are presented in Table 1 for the activity of 6a-6g against two strains of thymidine kinase-competent (TK + ) VZV and also two strains of ©2002 International Medical Press thymidine kinase-deficient (TK -) VZV. Data for the antiherpetic agent acyclovir (Figure 1 ) and our previously reported leads with an alkyl side-chain (1a-1c, McGuigan et al., 1999) and a p-alkylphenyl side-chain (2a-2g, McGuigan et al., 2000b) are included for reference. Cytotoxicity data are also given for each compound in two assays (Table 1) .
Discussion
It is apparent from the data in Table 1 that, despite compounds 6a-6g and 2a-2g being chemically isomeric, there is a significant reduction of antiviral potency for the analogues bearing terminal phenyl groups. Thus, comparing the lead (2e) from the p-alkylphenyl series to its isomeric pentyl-ω-phenyl compound (6e) reveals the latter compound to be ca. >30000 fold less potent than the earlier lead. This is despite 6e having what might be regarded as close to an optimal ClogP value of 2.3 . It is interesting to note that the two shortest chain homologues (6a-6b) are essentially inactive as antivirals, whilst the two longest chain homologues (6f-6g) are the most active, with EC 50 values of 0.01 µM for compound 6g. It is also of note that 6c appears slightly more active than the longer chain homologue 6d. However, the significance of this small difference is currently unclear.
However, 6f-6g are still significantly less active than the palkylphenyl counterparts 2f-2g.
Although there appears to be an optimal ClogP range of 2.4-3.5 for the p-alkylphenyl analogues (2a-2g), this is not the case for the w-phenyl-substituted derivatives, thus suggesting that lipophilicity, or ClogP, alone cannot reliably predict antiviral potency. We have previously suggested (McGuigan et al., 2001 ) that the enhancement of antiviral potency observed with the lead p-alkylphenyl systems (2a-2g), may be related to the restricted conformational freedom of the side-chain. It may be that the analogues bearing a phenyl ring directly attached to the furo ring of the bicyclic base more closely resemble an 'optimal' conformation at the VZV-encoded thymidine kinase active site (or target protein binding site) when compared to those that bear terminal phenyl groups in their sidechains. Using commercial software (MOPAC within Chem 3D Pro 5.0), we attempted to model the energyminimized conformations of representative analogues from series 2 and 6, in order to compare the relative orientations of the side-chains. Figure 3 shows a representation of the minimum energy conformations of 2e and 6e with the base and sugar portions overlaid to the maximum extent. The structures appear to show a significantly different conformation of the side-chain in each case, indicating the possibility that the side-chain occupies a different conformational space for the p-alkylphenyl series (2a-2g) versus the alkyl-ω-phenyl isomers (6a-6g). It is possible that this may correlate with the poorer antiviral activity in the latter series, as the side-chain may occupy non-optimal conformations, as compared to the lead series. A more thorough conformational search would be necessary to fully support this view, however, we believe that our preliminary observations are of interest as a possible rationalisation of the striking antiviral data and moreover as a potential predictive tool for antiviral potency.
As noted in all cases with other bicyclic analogues (McGuigan et al., 2001) , the present nucleosides displayed no antiviral activity in the thymidine kinase-deficient virus assays (Table 1) , which implies an absolute dependence on thymidine kinase-mediated activation for their biological activity. Substrate activity for VZV TK has indeed been demonstrated for several bicyclic nucleoside analogues, including lead compounds 1a and 2e (Sienaert et al., 2002; . Further evaluation of compounds 6a-6g (data not shown) showed a complete absence of antiviral activity in cell culture against human CMV, HSV-1 and HSV-2, and VV, indicating that the compounds are VZV-specific in their action. The results obtained here are rather disappointing but, nevertheless, are consistent with our previous suggestions regarding the importance of the conformation of the side-chain for antiviral activity (McGuigan et al, 2001) . Further modifications are being actively pursued in our laboratories on other bicyclic analogues bearing aromatic moieties in their sidechains. 
